跳至主要内容
临床试验/NCT03784378
NCT03784378已完成1 期

RXDX-105 for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring a RET Gene Fusion and a Patient With Ovarian Cancer Harboring a BRAF Gene Mutation

Memorial Sloan Kettering Cancer Center1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2018年12月14日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
3
试验地点
1
主要终点
Evaluation during treatment/intervention

研究概览

简要总结

This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • This individual patient protocol includes treatment for 3 patients previously enrolled on IRB #15-270 (phase1/1b clinical trial RXDX-105-01):

排除标准

  • Any patients other than those described above are excluded.

研究组 & 干预措施

Participants previously enrolled on Study of RXDX-105

Experimental

Participants were previously enrolled on Study of RXDX-105

干预措施: RXDX-105 (Drug)

结局指标

主要结局

Evaluation during treatment/intervention

时间窗: Through study completion, up to five years.

Safety assessments will be performed as standard of care and as clinically indicated. This will include monitoring of adverse events, including serious adverse events including CTCAE grading.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验